MYI vs IMMX Comparison

BLACKROCK MUNIYIELD QUALITY FUND III, INC. is an investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes, as is consistent with its investment policies and prudent investment management. The fund invests a majority of its assets in municipal obligations exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax). Under normal market conditions, the fund invests mainly in long-term municipal obligations that are investment-grade quality or are considered by the adviser to be of comparable quality at the time of investment. It can also invest directly in such securities or synthetically through the use of derivatives.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.